News

Geron Corp. quits stem cell work

 

The Menlo Park-based biotechnology firm Geron Corp. announced recently that it was abandoning its stem cell research in favor of focusing on two cancer drugs.

The motivation appears financial, according to a statement issued by the company.

"The decision to narrow Geron's technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities," the company said.

As a result, 66 jobs -- 38 percent of its workforce -- will be eliminated, the company said.

The news came as a blow to those hoping to benefit from stem cell therapy, a field that held promise for those paralyzed by spinal cord injuries.

Stem cells possess the ability to become any other type of cell in the body, leading Geron's scientists to explore how to grow the cells into replacement neurons that could reverse paralysis.

Comments

Sorry, but further commenting on this topic has been closed.

Greek restaurant Taverna opening in Palo Alto
By Elena Kadvany | 7 comments | 10,356 views

Retail's Real Estate Glut is Growing
By Steve Levy | 8 comments | 1,711 views

Couples: . . . “Joy is greater than sorrow,“ . . . “Nay, sorrow is the greater.”
By Chandrama Anderson | 1 comment | 1,116 views

Munchie Movement
By Laura Stec | 8 comments | 699 views

 

The Almanac Readers' Choice ballot is here

It's time to decide what local business is worthy of the title "The Almanac Readers' Choice" — and you get to decide! Cast your ballot online. Voting ends May 28th. Stay tuned for the results in the July 18th issue of The Almanac.

VOTE HERE